Avivax, a Paris-based biotechnology firm creating therapies for continual inflammatory ailments, noticed its shares rise 36% on Tuesday after saying new knowledge on its lead drug candidate, obefazimod.
The newest outcomes from the upkeep section of the Section 3 ABTECT trial confirmed that the experimental oral therapy produced “clinically significant enhancements” in adults with reasonable to extreme ulcerative colitis, together with sufferers who had beforehand failed to answer therapy.
After 44 weeks, 37.2% of sufferers who didn’t reply to the preliminary therapy section had achieved scientific remission, that means their signs had almost disappeared, and 34.5% had therapeutic of the intestinal lining.
The corporate stated 45.5% of sufferers whose illness returned after initially enhancing signs returned to remission after rising the dose to 50mg.
This replace comes simply weeks after Avivax’s inventory value plunged 44% on June 2 following the discharge of Section 3 security knowledge from the ABTECT upkeep examine.
The corporate additionally stated its present expanded security evaluation discovered that most cancers charges remained throughout the vary sometimes seen in sufferers with ulcerative colitis.
Based mostly on mixed security knowledge from section 2 and section 3 packages representing 1,704 years of affected person therapy, the incidence of most cancers, excluding non-melanoma pores and skin cancers, was 0.35 and 0.64 circumstances per 100 patient-years within the mixture therapy and 50 mg teams, respectively. For non-melanoma pores and skin cancers, the incidence was 0.59 and 0.64 circumstances per 100 patient-years.
The corporate stated the evaluation didn’t determine any new or sudden security alerts.
“The expanded cumulative security knowledge additional strengthens our confidence within the long-term security profile of obefazimod and strengthens the favorable benefit-risk profile for our program as we put together for our anticipated NDA submitting later this yr,” CEO Marc de Garidel stated in a press release.
Avivax stated it’s on monitor to file a brand new drug software for obefazimod with the U.S. Meals and Drug Administration within the fourth quarter of 2026.
The corporate can be evaluating obefazimod as a therapy for Crohn’s illness, one other type of inflammatory bowel illness, which might develop the chance past ulcerative colitis. Outcomes from the mid-term Section 2 trial are anticipated in mid-2027.
Avivax shares have been up 36% on the Paris market on Tuesday afternoon, buying and selling at 113.30 euros.
